

FIG. 1**Summary of FAM13A Variants Associated Independently with WHR**

Variant	Trait	P-Value	EAf	Population	Beta	N
rs57400569-A (intronic)	WHRadjBMI	1.95e-07	20.8	UK Biobank	-0.015	407,294
	Triglycerides	2.17e-09	22.1	Iceland, UK Biobank, Denmark	-0.0144	642,962
	HDL Cholesterol	9.13e-14	22.1	Iceland, UK Biobank, Denmark	0.02	611,021
	Systolic Blood Pressure	6.03e-10	22.1	Iceland, UK Biobank	-0.0169	509,398
	<i>FAM13A</i> Subcutaneous Adipose eQTL	5.23e-33	20.8	deCODE	-0.7409	
rs7657817-T (V443I missense)	WHRadjBMI	5.0e-09	18.5	Iceland, UK Biobank	-0.016	476,383
	Triglycerides	1.12e-09	16.4	Iceland, UK Biobank, Denmark	-0.0155	642,962
	HDL Cholesterol	5.11e-11	16.4	Iceland, UK Biobank, Denmark	0.0187	611,021
rs9991328-T (intronic)	WHRadjBMI	5.25e-31	47.0	UK Biobank	0.028	407,294
	Triglycerides	1.06e-16	49.8	Iceland, UK Biobank, Denmark	0.0164	642,962
	HDL Cholesterol	3.59e-32	49.8	Iceland, UK Biobank, Denmark	-0.0261	611,021
	<i>FAM13A</i> Subcutaneous Adipose eQTL	7.81e-20	40.2	deCODE	0.492	

FIG. 2A




FIG. 2B




FIG. 3A




FIG. 3B




FIG. 3C




FIG. 3D

Percent Knockdown at 30 mg/kg on Day 5

	D-0001	D-0002	D-0003
Subcutaneous WAT	59%	65%	58%
Epididymal WAT	52%	58%	59%
Liver	46%	57%	62%

FIG. 4A




FIG. 4B




FIG. 4C





FIG. 5**Effects of C16- and GalNAc-linked *Fam13a* siRNA In Obese Mice**

	Saline	C16-NT 30 mg/kg	C16- <i>Fam13a</i> 5 mg/kg	C16- <i>Fam13a</i> 30 mg/kg	GalNAc- NT 5 mg/kg	GalNAc- <i>Fam13a</i> 5 mg/kg	p-value C16- <i>Fam13a</i> (30 mg/kg) vs. GalNAc- <i>Fam13a</i> (5 mg/kg)
Body Weight (grams)	52.1	54.7	52.5	44.5****	53.8	46.0****	0.77
Fat Mass (grams)	20.7	22.6	21.8	14.9****	21.7	16.9***	0.51
Cumulative Food Intake (grams)	184.0	196.6	190.5	180.9	203.6	182.3**	0.999
Liver weight (grams)	2.7	3.1	2.7	1.9****	3.0	1.6****	0.39
Insulin (ng/mL)	12.0	15.6	8.4**	4.8****	12.3	4.2**	0.999
Total cholesterol (mg/dL)	255.8	276.8	265.4	204.9***	239.8	150.4****	0.0036
LDL cholesterol (mg/dL)	25.4	27.5	23.4	19.4**	23.0	14.6**	0.13
ALT (U/L)	169.1	245.4	121.6*	122.1*	275.4	109.4**	0.997

One-way ANOVA with Sidak's test for multiple comparisons for treatment vs respective NT control; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001

FIG. 6









FIG. 7K



FIG. 7L



FIG. 7M




FIG. 7N




FIG. 7O



FIG. 7P



FIG. 7Q




FIG. 7R



FIG. 8A




FIG. 8B




FIG. 8C




FIG. 8D




FIG. 9A




FIG. 9B




FIG. 9C




FIG. 10A




FIG. 10B




FIG. 11A




FIG. 11B




FIG. 11C




FIG. 11D




FIG. 11E

